ephedrine hydrochloride · Dr Reddys Labs Sa · NDA 213536
Rezipres
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213536 · 001 · RLD · discontinued | solution, intravenous | 23.5MG/5ML (4.7MG/ML) | open |
| 213536 · 002 · RLD · discontinued | solution, intravenous | 47MG/ML (47MG/ML) | open |
| 213536 · 003 · RLD · discontinued | solution, intravenous | 47MG/5ML (9.4MG/ML) | open |
| 213536 · 004 · RLD · discontinued | solution, intravenous | 47MG/10ML (4.7MG/ML) | open |